Redcliffe Labs Acquires Pune's Megavision Diagnostics for Rs 40 Crore, Expanding Access to Advanced Imaging

Omnichannel diagnostics provider Redcliffe Labs has acquired Pune-based Megavision Diagnostics Centre in a deal valued at approximately Rs 40 crore, a transaction the Noida-headquartered company says will strengthen its radiology and imaging capabilities while expanding integrated diagnostic access across western India.

Founded in 1996, Megavision Diagnostics operates two diagnostic centres in Pune's Pimpri and Nigdi areas, offering MRI, CT scans, mammography, sonography, ECG and EEG services, and generates annual revenue of around Rs 20 crore. As part of the acquisition, Redcliffe Labs will retain Megavision's entire workforce, and Dr Kedar Prabhakar Bhate, the diagnostic centre's founder and director, will continue leading Megavision's operations under the Redcliffe umbrella while working alongside Redcliffe's Clinical Board to strengthen radiology services and expand integrated diagnostics across Pune and the surrounding region.

"Building Megavision Diagnostics has been a journey of trust, relationships, and an unwavering commitment to quality healthcare," said Dr Bhate. "As we become part of the Redcliffe Labs family, I am confident that our shared values of patient-centric care and diagnostic excellence will enable us to build on Megavision's legacy while preserving the trust and standards that have defined us for over two decades."

Speaking to media about the acquisition, Redcliffe Labs co-founder and CEO Aditya Kandoi said the deal will allow the company to expand beyond pathology into integrated diagnostics by adding services such as MRI, CT scans, ECG, EEG and mammography to its portfolio. "Earlier, we were only offering pathology services," Kandoi noted, framing the move as part of a deliberate strategy to build a single platform where patients can access both laboratory and imaging diagnostics rather than being referred between separate providers for different categories of tests, an integration that can materially reduce both the time and cost burden patients face when navigating a diagnosis that requires multiple types of testing.

Founded in 2018 by Kandoi and Dheeraj Jain, Redcliffe Labs has grown into one of India's fastest-expanding diagnostics companies, offering more than 3,600 pathology tests alongside genetic and preventive health screening services, and says it has served more than one crore customers across over 220 cities through more than 80 owned laboratories covering more than 4,000 pincodes. The company is targeting nearly 50 per cent year-on-year growth to reach approximately Rs 700 crore in revenue in FY27, a target it is pursuing through a combination of organic expansion and an increasingly active acquisition strategy.

The Megavision deal follows Redcliffe's recent acquisitions of Prime Sonography and Diagnostic Center in Kota and Sarvodaya Diagnostics in Ajmer, both of which now operate under the company's Redcliffe Medicentre Imaging & Labs banner, continuing a pattern of acquiring established regional diagnostic operators rather than building new imaging centres from scratch in each new market. That approach allows Redcliffe to leverage existing local reputations, trained staff and installed imaging equipment, meaningfully compressing the time it would otherwise take to establish trusted diagnostic infrastructure in a new city.

Redcliffe's willingness to retain existing clinical leadership and workforce through its acquisitions, as it has done with Dr Bhate at Megavision, reflects a deliberate strategy of preserving the local trust and clinical relationships that took decades for founder-led diagnostic centres to establish, rather than attempting to rebrand or restructure acquired assets immediately under a single national identity. That approach carries particular importance in diagnostics, a category where patients and referring physicians alike tend to place significant weight on the specific clinicians and technicians involved in a test, not merely the corporate brand behind the facility, making continuity of leadership a genuine commercial asset rather than a mere goodwill gesture. That same logic extends to Redcliffe's broader acquisition playbook: by consistently retaining founder-clinicians in senior operating roles across its acquired centres, the company is effectively building a federated network of respected regional clinical leaders under a shared national infrastructure and brand, rather than pursuing the more centralised, top-down integration model that has historically characterised hospital-chain consolidation in India.

For India's broader healthcare access landscape, the wave of diagnostics consolidation now underway carries real implications for patients beyond the immediate transaction economics. As standalone regional diagnostic centres are absorbed into larger national networks with greater capital access, patients increasingly gain access to a broader range of integrated pathology and imaging services under a single provider relationship, potentially reducing the fragmentation and repeat-visit burden that has historically characterised India's diagnostics sector, where patients seeking both laboratory and imaging tests have often had to navigate entirely separate providers, referral processes and billing systems for what is, from the patient's perspective, a single diagnostic journey. For patients across Pune's Pimpri-Chinchwad belt specifically, the practical outcome of the Redcliffe-Megavision deal is straightforward: continuity of an established, trusted imaging provider now backed by a larger national network's resources, positioned to expand access to advanced diagnostic imaging in a region where such capacity has historically been concentrated among a small number of independent operators. As Redcliffe continues pursuing its stated Rs 700 crore FY27 revenue target through this blend of organic growth and disciplined regional acquisitions, the Megavision deal offers a useful template for how the company intends to scale: identifying established, trusted, profitable regional operators, retaining their clinical leadership and workforce, and layering the resulting network onto Redcliffe's existing national pathology infrastructure rather than attempting to displace local incumbents entirely. Backed by investors including IFU, LeapFrog Investments, HealthQuad, Spark Growth Ventures and Chiratae Ventures, Redcliffe has the balance sheet to continue pursuing this acquisition-led strategy at pace, and the Megavision transaction is unlikely to be its last as India's diagnostics consolidation wave continues to unfold through the remainder of 2026.